Abstract
Background: Multiple Myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of malignant plasma cells (PCs). Flow cytometry is an essential tool to confirm diagnosis and evaluate minimal residual disease (MRD). This study aims at identifying new surface PC markers suitable for targeted therapy in MM and able to improve MRD detection. Methods: The expression of 82 molecules provided by the "Ninth International Workshop on Leukocyte Antigens" was analyzed by flow cytometry in 5 MM cell lines and in 20 newly diagnosed MM (NDMM) patients. Based on the antigens expression and monoclonal antibody availability, CD150, CD48, CD229, CD352, CD319, CD272, CD86, CD200 and CD184 were subsequently tested in 24 NDMM, 8 relapsed MM (RMM), 6 plasma cell leukemia (PCL) and 13 healthy subjects. Results: CD352 was less frequently expressed on NDMM than on healthy PCs; CD200 was more frequently expressed on NDMM than on RMM and healthy PCs. CD150, CD319, CD229, CD352 Mean Fluorescence Intensity (MFI) was lower in pathological than in healthy samples. The proportion of CD150-positive samples was lower in NDMM and RMM than in healthy subjects; CD86+ samples were less frequent in NDMM than in healthy subjects; CD200+ samples were more frequent in NDMM than in RMM and healthy subjects. Conclusions: CD150, CD86 and CD200 can help to identify malignant PCs; CD272, CD319, CD229, CD48 are highly expressed on all PCs and could be considered for targeted therapy. All these antigens could be added to a routine panel for PCs identification and MRD evaluation.
| Original language | English |
|---|---|
| Pages (from-to) | 81 |
| Number of pages | 90 |
| Journal | Cytometry Part B - Clinical Cytometry |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
Keywords
- CD150
- CD272
- Multiple myeloma
- Plasma cell immunophenotype
- SLAM
ASJC Scopus subject areas
- Cell Biology
- Histology
- Pathology and Forensic Medicine
Cite this
Multiple myeloma : New surface antigens for the characterization of plasma cells in the era of novel agents. / Muccio, Vittorio Emanuele; Saraci, Elona; Gilestro, Milena; Gattei, Valter; Zucchetto, Antonella; Astolfi, Monica; Ruggeri, Marina; Marzanati, Eleonora; Passera, Roberto; Palumbo, Antonio; Boccadoro, Mario; Omedè, Paola.
In: Cytometry Part B - Clinical Cytometry, 2016, p. 81.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multiple myeloma
T2 - New surface antigens for the characterization of plasma cells in the era of novel agents
AU - Muccio, Vittorio Emanuele
AU - Saraci, Elona
AU - Gilestro, Milena
AU - Gattei, Valter
AU - Zucchetto, Antonella
AU - Astolfi, Monica
AU - Ruggeri, Marina
AU - Marzanati, Eleonora
AU - Passera, Roberto
AU - Palumbo, Antonio
AU - Boccadoro, Mario
AU - Omedè, Paola
PY - 2016
Y1 - 2016
N2 - Background: Multiple Myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of malignant plasma cells (PCs). Flow cytometry is an essential tool to confirm diagnosis and evaluate minimal residual disease (MRD). This study aims at identifying new surface PC markers suitable for targeted therapy in MM and able to improve MRD detection. Methods: The expression of 82 molecules provided by the "Ninth International Workshop on Leukocyte Antigens" was analyzed by flow cytometry in 5 MM cell lines and in 20 newly diagnosed MM (NDMM) patients. Based on the antigens expression and monoclonal antibody availability, CD150, CD48, CD229, CD352, CD319, CD272, CD86, CD200 and CD184 were subsequently tested in 24 NDMM, 8 relapsed MM (RMM), 6 plasma cell leukemia (PCL) and 13 healthy subjects. Results: CD352 was less frequently expressed on NDMM than on healthy PCs; CD200 was more frequently expressed on NDMM than on RMM and healthy PCs. CD150, CD319, CD229, CD352 Mean Fluorescence Intensity (MFI) was lower in pathological than in healthy samples. The proportion of CD150-positive samples was lower in NDMM and RMM than in healthy subjects; CD86+ samples were less frequent in NDMM than in healthy subjects; CD200+ samples were more frequent in NDMM than in RMM and healthy subjects. Conclusions: CD150, CD86 and CD200 can help to identify malignant PCs; CD272, CD319, CD229, CD48 are highly expressed on all PCs and could be considered for targeted therapy. All these antigens could be added to a routine panel for PCs identification and MRD evaluation.
AB - Background: Multiple Myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of malignant plasma cells (PCs). Flow cytometry is an essential tool to confirm diagnosis and evaluate minimal residual disease (MRD). This study aims at identifying new surface PC markers suitable for targeted therapy in MM and able to improve MRD detection. Methods: The expression of 82 molecules provided by the "Ninth International Workshop on Leukocyte Antigens" was analyzed by flow cytometry in 5 MM cell lines and in 20 newly diagnosed MM (NDMM) patients. Based on the antigens expression and monoclonal antibody availability, CD150, CD48, CD229, CD352, CD319, CD272, CD86, CD200 and CD184 were subsequently tested in 24 NDMM, 8 relapsed MM (RMM), 6 plasma cell leukemia (PCL) and 13 healthy subjects. Results: CD352 was less frequently expressed on NDMM than on healthy PCs; CD200 was more frequently expressed on NDMM than on RMM and healthy PCs. CD150, CD319, CD229, CD352 Mean Fluorescence Intensity (MFI) was lower in pathological than in healthy samples. The proportion of CD150-positive samples was lower in NDMM and RMM than in healthy subjects; CD86+ samples were less frequent in NDMM than in healthy subjects; CD200+ samples were more frequent in NDMM than in RMM and healthy subjects. Conclusions: CD150, CD86 and CD200 can help to identify malignant PCs; CD272, CD319, CD229, CD48 are highly expressed on all PCs and could be considered for targeted therapy. All these antigens could be added to a routine panel for PCs identification and MRD evaluation.
KW - CD150
KW - CD272
KW - Multiple myeloma
KW - Plasma cell immunophenotype
KW - SLAM
UR - http://www.scopus.com/inward/record.url?scp=84945275358&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945275358&partnerID=8YFLogxK
U2 - 10.1002/cyto.b.21279
DO - 10.1002/cyto.b.21279
M3 - Article
AN - SCOPUS:84945275358
SP - 81
JO - Cytometry Part B - Clinical Cytometry
JF - Cytometry Part B - Clinical Cytometry
SN - 1552-4949
ER -